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ABSTRACT
Uptake and dose distributions in peritoneal LS174T colon tumor xenografts were compared for a hu-
manized construct of the CC49 (HuCC49) high-affinity anti-TAG-72 monoclonal antibody and a construct
with the CH2 region deleted (HuCC49DCH2), both labeled with 177Lu using a PA-DOTA bifunctional
chelating agent and injected in the peritoneum. Tumors were resected and serially sectioned at 1 h, 4 h,
24 h, and 48 h postinjection. Between 5 and 24 (average 16) sections were retained per tumor for au-
toradiography. The typical section interval was 340 mm and thickness was 16 mm. Tumor sections were
air dried and placed on film and/or phosphor screen. Section images were digitized at 100 mm resolu-
tion electronically (phosphor screen) or by laser densitometer (film). Section images were used to gen-
erate tumor surface descriptions and activity distributions by reconstructing the activity densities in three
dimensions. Three-dimensional dose-rate calculations, performed using a point kernel for 177Lu, were
used to prepare radial histograms describing the variation in dose rate as a function of distance from the
tumor center to surface. At early times postinjection, the 177Lu-HuCC49DCH2 antibody displayed higher
dose rates near the tumor surface compared to the 177Lu-HuCC49 antibody. At 24 h postinjection, dose
rate distributions appeared similar for both antibodies and more uniform than at earlier times. The 177Lu-
HuCC49DCH2 antibody indicated improved uniformity at 48 h postinjection. Cell survival calculations
based on the three-dimensional dose rate distributions favored 177Lu-HuCC49DCH2 for equal injection
activities. However the most significant effect was the greater injected dose tolerated for the 177Lu-
HuCC49DCH2 antibody based on equivalent estimated bone marrow dose.
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INTRODUCTION
Changes in the delivery systems and isotopes
used for radioimmunotherapy of cancer have a
significant impact on outcome. Predicted and ac-
tual therapy results can be better understood us-
ing detailed dosimetric studies. It is hoped that
future therapy regimen designs can benefit from
improved dosimetric analyses.
Limitations to the use of radioimmunotherapy
for the treatment of cancer have included the hu-
man anti-murine antibody (HAMA) response due
to the use of murine mAbs, myelotoxicity due to
slow clearance of the radiolabeled mAbs from
serum, and slow and nonuniform uptake of mAbs
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in tumor. A greater choice of radioisotopes
(177Lu, 64/67Cu, 186/188Re, 90Y) followed the de-
velopment of improved bifunctional chelating
agents capable of forming highly stable com-
plexes with radiometals.1 These isotopes (except
90Y) have potentially favorable beta and photon
characteristics and lack the in vivo deiodination
of 131I. The HAMA response in patients has been
mitigated through genetically engineered mAbs,
particularly humanized mAbs with only the anti-
gen-binding complementary-determining region
from the native murine mAbs.2,3 However, the hu-
manized mAbs may produce increased myelo-
toxicity due to even slower clearance from serum.
Myelotoxicity can be decreased by increasing
the serum clearance of mAbs through decreased
molecular size. Decrease in molecular size has
been achieved through the use of mAb fragments
and genetically engineered single-chain variable
regions. Drawbacks include increased radiation
dose to kidneys, lower antigen affinity, and de-
creased radiation dose to the tumor due to lower
binding rates and increased clearance from tu-
mor. A potential advantage is increased uptake
uniformity in tumor due to improved mobility.
Another option to reduce molecular size is to
delete the CH1 or CH2 domain of the constant
region of the mAb, which is replaced with a pep-
tide linker. It has been postulated that more rapid
serum clearance occurs not only because of de-
creased molecular size, but also because of re-
moval of the glycosylation site in the CH2 re-
gion, which may facilitate receptor-mediated
clearance through the liver.4 The use of a hu-
manized mAb with CH2 region deleted may im-
prove therapeutic results through lower immuno-
genicity, rapid blood clearance, and comparable
tumor localization.
CC49 is a second-generation murine mAb re-
active with the TAG-72 antigen, present on a va-
riety of adenocarcinomas. It has a higher binding
affinity for TAG-72 compared to its precursor
mAb, B72.3, and has been radiolabeled with 131I,
90Y, and 177Lu.5–7 Lutetium-177 has a 6.7-day
half-life, a maximum beta emission of 497 keV
and relatively low branching ratios for gamma
emissions, useful for imaging. The lower energy
beta spectrum of 177Lu, compared to 131I, in-
creases dose rates at tumor surface regions, but
provides less radiation cross-talk in more central,
low-uptake regions.8 However, the expected im-
proved uniformity of uptake for the CH2-deleted
mAb may favor the less penetrating beta spec-
trum, particularly in tumor surface regions.
We report on comparative dosimetry studies
for peritoneal LS174T colon tumor xenografts,
receiving 177Lu-PA-DOTA-HuCC49 or 177Lu-
PA-DOTA-HuCC49DCH2 mAbs by intraperi-
toneal injection. The dosimetric comparison will
focus on the changes in three-dimensional (3D)
dose-rate distributions with time postinjection.
MATERIALS AND METHODS
Tumor Model
Four- to five-week-old athymic nude mice (Na-
tional Cancer Institute Frederick Research Labo-
ratory, Frederick, MD), implanted i.p. with 5 x
107 LS174T cells, received an i.p. injection of
177Lu-PA-DOTA-HuCC49 or 177Lu-PA-DOTA-
HuCC49DCH2 (30 mCi to 300 mCi) 8 days post
tumor-cell injection. Additional experimental de-
tails and biodistribution data are presented else-
where.9
Tumors were resected, frozen and serially sec-
tioned at 1 h, 4 h, 24 h, and 48 h postinjection
with 177Lu-PA-DOTA-HuCC49 or 177Lu-PA-
DOTA-HuCC49DCH2 mAbs. Between 5 and 24
(average 16) sections were retained per tumor for
autoradiography. The typical interval between
sections was 340 mm. Section thickness was 16
mm. Tumor sections were air dried and placed on
film (Super RX 20.3 x 25.4 cm, FujiFilm, Stam-
ford, CT ) and/or phosphor screen (BAS-MS
Imaging Plates 20 x 25 cm with BAS-1800 scan-
ner, FujiFIlm, Stamford, CT) for autoradiogra-
phy. Section images from film were digitized at
100 mm resolution using a laser densitometer
(Lumysis, Sunnyvale, CA). Phosphor imager
pixel resolution was set to 100 mm. Film and
phosphor screen responses were measured using
gel samples with known activity density, which
were sectioned and imaged along with the tumor
sections.
Activity Density Distributions
Three-dimensional activity and dose-rate distrib-
utions were generated using image-based treat-
ment planning software written by the University
of Michigan (UMPLAN) together with adjunct
software designed specifically to work with UM-
PLAN. Serial sections for each tumor were im-
aged together in approximate alignment. The po-
sitions of the electronic section images were
translated and rotated to produce optimum align-
ment. Optimum alignment was determined based
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on external contour and internal structure match-
ing via operator judgment and independent re-
view. Spaces between section images were de-
termined from gaps skipped between sections.
Tumor surface descriptions were generated by
autocontouring of the digitized section images
and using 3D surface-rendering software within
UMPLAN. The first and last contours were
capped corresponding to approximately half a
sectioning interval. Surface contour generation
criteria were checked by comparing the results to
a sampling of optically scanned images of sec-
tion slides. The reconstructed tumor volumes
were compared for consistency to the tumor
masses measured before sectioning. Section im-
ages, image intensity calibration curves, and
alignment parameters were used to create 3D ac-
tivity density distributions. A linear interpolation
of activity density information between sections
filled the 3D activity density matrix. The activ-
ity density distributions were superimposed on
section images to check proper alignment and ap-
proximate activity density magnitudes.
Three-dimensional dose-rate distributions were
calculated using a point kernel for 177Lu.10 Voxel
kernels were calculated by distributing 64 point
kernels in the voxel volume. The voxel kernel
was folded with the activity density matrix using
Fast Fourier analysis. Most tumor matrices were
summed to a (0.2 mm)3 cubic voxel for the dose
rate calculation due to limitations on matrix size
imposed by UMPLAN (128 x 128 x 128). Dose
calculations for the remainder (smaller tumors)
were performed using the original (0.1 mm)3
voxel. The results of dose-rate calculations were
superimposed on the section images as a check
on alignment and approximate dose-rate magni-
tudes. Detailed procedures have appeared else-
where.11,12
Dosimetry Model
The dose-rate information was used to prepare ra-
dial histograms describing the variation in dose
rate as a function of fractional distance from the
tumor center of mass to the tumor surface. The
histograms represent dose-rate distributions for
30 radial increments. This procedure isolated sur-
face compared to central tumor uptake charac-
teristics. Some tumors appeared as two or three
separate nodules rather than one solitary nodule.
These were treated as separate tumors, or were
discarded as unusually small ancillary nodules.
Radial histograms were averaged to produce
dose-rate descriptions representative of average
behavior at each time point postinjection. His-
tograms were normalized to the average dose rate
values calculated from the tumor uptake mea-
surements (Fig. 1b). The range of dose rates ob-
served was preserved in the average, whether for
a smaller than average tumor or a larger than av-
erage tumor.
The radially dependent histograms and the av-
erage dose rates derived from the uptake curves
together represented the spatially and temporally
varying dose-rate description. For times between
measured uptake distributions, linear interpola-
tion of the dose-rate distributions was performed.
The averaged dose-rate data represented an ide-
alized history of a representative tumor.
Tumor dose rates were summed over time to
yield cumulative dose distributions. Each radial
increment was summed with like radial incre-
ments from the other averaged histograms. In
each radial increment, dose rates were summed
assuming the approximation of maximum het-
erogeneity. This is equivalent to assuming that
well and poorly vascularized regions remained
distinct during the time course of the idealized
tumor. Detailed procedures have appeared else-
where.12,13
Effective Dose
Effective dose calculations were performed using
the dosimetry model. The effective dose was de-
fined as the uniform dose required for an equiv-
alent minimum fractional cell survival (S), as-
suming a linear (a) dose response:
Deff 5 21/a[ln(S)]min
For a temporally and spatially varying dose dis-
tribution:






where RE is the relative effectiveness factor as-
suming the linear quadratic model14,15 and V is
the tumor volume.
Cell survival calculations also assumed an ap-
proximate relative cell proliferation rate based on
observed fractional necrotic volumes of ,30%.
Fractional volume functions for necrotic, hy-
poxic, and oxygenated cells were derived as a
function of vessel spacing. The hypoxic and
necrotic partial volumes were estimated by fold-
ing the fractional volume function with the vas-
cular density function. The normalization was ad-
justed to yield a 0.3 fractional necrotic volume,
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resulting in a net fractional hypoxic volume of
0.1. The fraction of oxygenated cells increased
from the interior (,0.5) to the surface (,0.7)
with the corresponding decrease in necrotic cells.
Oxygenated cells were assumed to proliferate
while hypoxic cells remained dormant. Cell sur-
vival equations were:












and the subscripts represent oxygenated and hy-
poxic components, necrotic cells do not contrib-
ute to S, FO and FH are the radially dependent
fractional volumes, and l is the cell proliferation
constant. The linear quadratic parameters were
derived so that the tumor cell loss was repre-
sented by an average a of 0.3 Gy21 and a/b of
25 Gy. The cell repair constant was 0.46 h21. The
cell proliferation constant was derived from tu-
mor regrowth data taken for single fraction 60Co
experiments for this tumor model. More detail on
the calculation method appears in the litera-
ture.13,15
Comparison Dosimetry
For purposes of comparing dose calculations be-
tween studies, it is assumed that the bone mar-
row is the dose limiting normal organ. The 177Lu
radionuclide conjugated to murine CC49 antibody
experienced high tumor uptake and low bone up-
take.16 The dose to bone marrow is assumed pro-
portional to the dose to blood,17 which is depen-
dent on the uptake in blood (Fig. 1a). The ratios of
dose to bone marrow for the 177Lu-PA-DOTA-
HuCC49 and 177Lu-PA-DOTA-HuCC49DCH an-
tibodies are 3.7 and 2.2 for the nonpenetrating only
and the penetrating plus nonpenetrating compo-
nents. The difference in bone marrow response
in the mouse is expected to be consistent with the
total dose (penetrating plus nonpenetrating).
However, in the human, the whole body pene-
trating/nonpenetrating dose ratio is expected to
be lower due to the distance between marrow
sites and organs of highest concentration. An in-
termediate dose to bone marrow ratio of 3 was
chosen for the comparison.
RESULTS
Example autoradiographs are shown in Figure 2
for 4 h (panels a and b), 24 h (panels c and d),
and 48 h (panels e and f) postinjection for the
177Lu-PA-DOTA-HuCC49DCH2 and 177Lu-PA-
DOTA-HuCC49 antibodies, respectively. Uptake
becomes more uniform with time for both.
The 3D dose calculations use the average up-
take as a function of time (Fig. 1b) as input to
determine the time course of the tumor activity
density per injected dose. The 3D dose-rate in-
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Figure 1. Measured uptake curves for a) Blood, and b) Tumor for 177Lu-PA-DOTA-HuCC49DCH2 and 177Lu-PA-DOTA-
HuCC49.
formation is contained in the radial histograms,
averaged over multiple tumors (histograms ap-
pear elsewhere).9 The numbers of tumors digi-
tally reconstructed at 1 h, 4 h, 24 h, and 48 h
postinjection were 5, 6, 8, and 6 for the 177Lu-
PA-DOTA-HuCC49DCH2 experiments and 3, 5,
9, and 6 for the 177Lu-PA-DOTA-HuCC49 ex-
periments, respectively.
Average radial dose-rate curves derived from
the radial histograms illustrate general properties
of the time dependence (Fig. 3). They are plot-
ted in cGy/h/mCi to illustrate the change of dose
rate over time as a function of radius. At early
times, the dose rate peaks at radii near but not at
the tumor surface. Central dose rates increase
slowly and reach a plateau at later times. The
177Lu-PA-DOTA-HuCC49DCH2 antibody re-
tains greater uniformity of dose rate for a longer
time. The dose rates at the far surface regions re-
main lower for both antibodies because surface
dose rates are more a function of the isotope’s
beta spectrum than uptake characteristics. Be-
cause of the 3D partial volume increase with ra-
dial increment, the dose rate at the largest radial
increment represents nearly 10% of the tumor
volume.
The uptake curve for 177Lu-PA-DOTA-
HuCC49DCH2 falls at 24 h, then rises at 48 h.
This behavior cannot be attributed solely to
nonuniformity of uptake since the average non-
uniformity curves (Fig. 3) normalized to the up-
take measurements indicate an average increase at
all radii. This apparent discrepancy is probably due
to statistical fluctuations in the uptake data.
Due to the severe nonuniformity of dose rate,
both as a function of radius and range at each ra-
dius, the calculation of total dose is not mean-
ingful. Effective dose calculations were per-
formed for a range of injected doses, using the
minimum of the fractional cell survival curve. In-
jected doses were chosen for the 177Lu-PA-
DOTA-HuCC49 analysis and three times those
values for 177Lu-PA-DOTA-HuCC49DCH2. The
predicted whole-tumor fractional cell survival
reaches a minimum at about 50 h, with the min-
imum occurring at earlier times for larger injected
doses (Fig. 4). General characteristics of lower
relative efficacy for higher injected dose is evi-
dent by the greater gap between the lower and in-
termediate injected dose curves compared to the
intermediate and higher injected dose curves.
A direct comparison of the two antibodies for
the same injected dose illustrates the effect of the
difference in uptake patterns (Fig. 5). The differ-
ence between curves is due to the difference in
uptake and nonuniformity of uptake. All other pa-
rameters in the calculation were kept constant.
The 177Lu-PA-DOTA-HuCC49DCH2 antibody
achieves a greater recurrence delay, but a similar
curve minimum compared to the 177Lu-PA-
DOTA-HuCC49 antibody. The improved unifor-
mity of uptake noted in the radial distributions
does not impact the estimated cell survival until
after the minimum has been reached.
243
Figure 2. Section images of tumors resected at 4 h (a and b), 24 h (c and d), and 48 h (e and f) postinjection for 177Lu-PA-
DOTA-HuCC49DCH2 and 177Lu-PA-DOTA-HuCC49, respectively.
USE THIS BOX STYLE FOR
ALL TABLES AND ART SET
BY TWO COLUMNS
Figure 4. Predicted fractional whole tumor cell survival
vs. injected dose for a) 177Lu-PA-DOTA-HuCC49DCH2
and b) 177Lu-PA-DOTA-HuCC49. Injected dose levels were
chosen for comparison assuming approximately equivalent
bone marrow doses.Figure 3. Average radial distributions at 1 h, 4 h, 24 h, and
48 h postinjection for a) 177Lu-PA-DOTA-HuCC49DCH2 and
b) 177Lu-PA-DOTA-HuCC49.
The estimated fractional cell survival had a
considerable radial dependence. Figure 6 shows
five sample radii from the surface to near center
at regular intervals. At time zero, the fractions of
cells are normalized to partial volumes of a
sphere. The closer to the tumor surface, the ear-
lier the cell survival minimum and cell number
recovery occurs for both antibodies. The corre-
sponding calculations for the lowest injected
doses have the surface regions recurring first with
the effect getting stronger with increasing in-
jected dose. At later times the fractional volume
increases with increasing radius, making this ef-
fect dominant.
Estimated effective doses are given in Table 1.
Effective dose varies nonlinearly with injected dose
due to exponential cell loss with increasing dose
and nonuniform uptake and dose rates. These an-
tibodies yield similar results in predicted therapeu-
tic effect, as described by effective dose, for the
same injected dose. An effective dose based on
time to viable cell recurrence would be more fa-
vorable for the 177Lu-PA-DOTA-HuCC49DCH2
antibody.
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Figure 6. Fractional cell survival for selected radii for a)
177Lu-PA-DOTA-HuCC49DCH2 and b) 177Lu-PA-DOTA-
HuCC49. The sum for all radii at time zero is unity.
Figure 5. Comparison of fractional cell survival for 177Lu-
PA-DOTA-HuCC49DCH2 and 177Lu-PA-DOTA-HuCC49
antibodies. An injected dose of 300 mCi is assumed.
DISCUSSION
The nonuniformity of dose and dose rate in tu-
mor is a major concern for radioimmunotherapy.
Both the total uptake and nonuniform distribu-
tion must be measured to provide a reliable esti-
mate of tumor dosimetry. Since average total
dose does not correlate with outcome, a dosime-
try model using an effective or equivalent dose
definition is justified.
The dosimetry model used here is approximate
but useful for comparison of antibody behavior.
The difference in magnitude and uniformity of
uptake can be described in more useful terms as
a difference in predicted minimum cell survival
or time to viable cell recurrence. The result from
this comparison, that the faster clearance from
blood allowing greater injected dose values far
outweighs improvement in outcome due to more
uniform uptake, is important for the future opti-
mization of radioisotope carriers. However, the
improvement in 3D uptake characteristics is also
important for optimized therapy.
The predicted cell loss curves show a minimum
at about 2 days postinjection. This implies that
fractionated therapy using about this frequency
would yield an improved outcome. If so, the im-
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Table 1. Effective Dose and Time to Minimum Cell Survival
177Lu-HuCC49DCH2 177Lu-HuCC49
Injected dose, Injected dose,
mCi Time, hr Deff, Gy mCi Time, hr Deff, Gy
300 66 4.1 100 57 1.7
900 51 5.7 300 57 4.2
3000 18 6.9 1000 36 6.2
provement in dose uniformity observed for the
177Lu-PA-DOTA-HuCC49DCH2 antibody im-
plies that further improvement in outcome could
be achieved with additional fractions compared
with the 177Lu-PA-DOTA-HuCC49 antibody.
The significant uptake nonuniformity observed
in these studies changes with radius, but is pres-
ent at all radii. The dose rates at the tumor sur-
face are variable, but also systematically lower
than more interior dose rates. The lower average
dose rate at the tumor surface is predicted to be
the weak point in fractional cell loss. As time
postinjection increases, the predominantly viable
cell population at the well-vascularized surface
multiplies more rapidly. The average surface
dose rates are always lower than more interior
dose rates, and ultimately the surface experiences
the lowest average dose rate in the tumor. The
combination produces the predicted surface re-
currence. Others have observed the dominant ef-
fect of surface recurrence in histological stud-
ies.18
The shortcomings in the tumor model used here
include an approximate relationship between
necrotic and hypoxic cells and dose rate. The
model assumes that there is no correlation be-
tween dose rate and cell status. However, since
hypoxic cells are more likely to be far from ves-
sels, early uptake is expected to correlate with
cell status. At later times, this correlation is ex-
pected to decrease because of molecular diffu-
sion and convection producing greater relative
uptake uniformity. The model assumes that all of
the nonuniformity is due to random tumor archi-
tecture. The model also assumes that low-uptake
regions stay low-uptake regions. While this as-
sumption sounds reasonable, the greater the in-
jected dose, the greater the outcome depends on
the low-uptake regions and thus the more unreli-
able the model becomes.
The proportion of hypoxic and necrotic regions
varies with tumor size and with level of therapy,
but is assumed to remain constant in this model.
The proportions were set to approximately rep-
resent average tumor size. The critical compari-
son between antibody treatments occurs within 3
days, a time period unlikely to allow a big change
in the cell fractions. Extrapolating the present
data to therapy levels is of interest, but is ex-
pected to be less reliable because the tumor goes
through more rapid changes due to early cell loss,
probably beyond a couple of cell doubling times
(,5 days). This is not expected to impact the
minima in the cell loss curves for a bolus injec-
tion. The net affect of the proportion and radial
dependence of hypoxic and necrotic cells in this
model is to increase the importance of cells closer
to the tumor surface, which is closer to reality
than the assumption of uniform cell composition.
The result that the impact of rapid blood clear-
ance for the smaller molecule is more important
than the improvement in nonuniformity of uptake
may not be applicable to other tumor-antibody
models. If the antibody penetration were very
poor for the intact molecule, then the improve-
ment in nonuniformity achieved by the smaller
molecule could be more dramatic and possibly
dominant. In addition, the improvement in
nonuniformity may be more important in larger
tumors than presently studied for this tumor-an-
tibody model.
CONCLUSIONS
The comparison of the 177Lu-PA-DOTA-
HuCC49DCH2 and 177Lu-PA-DOTA-HuCC49
antibodies shows an observable advantage for the
HuCC49DCH2 antibody in terms of improved
dose rate due to more uptake uniformity. How-
ever the much larger advantage is the rapid blood
clearance, allowing approximately three times the
tolerated injected dose, assuming bone marrow
as the critical organ. The tumor surface is pre-
dicted to be the primary region of recurrence for
both antibodies.
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